HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations

Antiviral Therapy

Volumn 15, Issue 4, 2010, Pages 641-650

  Aulicino, Paula C ^a   Rocco, Carlos A ^a   Mecikovsky, Debora ^a   Bologna, Rosa ^a   Mangano, Andrea ^a   Sen, Luisa ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

POL PROTEIN; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; ANTIVIRAL RESISTANCE; ARGENTINA; ARTICLE; CODON; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MOLECULAR INTERACTION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; CHILD; DNA SEQUENCE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HIV INFECTIONS; MOLECULAR GENETICS; MUTATION; TRANSMISSION; VERTICAL TRANSMISSION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ARGENTINA; CHILD; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MOLECULAR SEQUENCE DATA; MUTATION; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 77956860296     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1571     Document Type: Article

References (28)

1. Jeeninga RE, Keulen W, Boucher C, Sanders RW, Berkhout B. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect. Virology 2001; 283:294-305.
2. Caliendo AM, Savara A, An D, DeVore K, Kaplan JC, D'Aquila RT. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J Virol 1996; 70:2146-2153.
3. Caride E, Hertogs K, Larder B, et al. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of HIV type 1 found in Brazilian patients failing HAART. Virus Genes 2001; 23:193-202.
4. Ariyoshi K, Matsuda M, Miura H, Tateishi S, Yamada K, Sugiura W. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01-AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr 2003; 33:336-342. (Pubitemid 36859059)
5. Kantor R, Katzenstein DA, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2:e112.
6. Gomez Carrillo M, Pampuro S, Duran A, et al. Analysis of HIV type 1 diversity in pregnant women from four Latin American countries. AIDS Res Hum Retroviruses 2006; 22:1186-1191.
7. Vignoles M, Barboni G, Agosti MR, et al. High frequency of major mutations associated with antiretroviral drug resistance in recently diagnosed HIV-infected children. Antivir Ther 2007; 12:1133-1137.
8. Petroni A, Deluchi G, Pryluka D, et al. Update on major HIV-1 resistance in Argentina: emergence of mutations conferring high-level resistance to non-nucleoside reverse transcriptase inhibitors in drug-naive patients. J Acquir Immune Defic Syndr 2006; 42:506-510.
9. Quarleri JF, Rubio A, Carobene M, et al. HIV type 1 recombinant strains exhibit different pol gene mosaic patterns: descriptive analysis from 284 patients under treatment failure. AIDS Res Hum Retroviruses 2004; 20:1100-1107.
10. Carobene MG, Rubio AE, Gomez Carrillo M, et al. Differences in frequencies of drug resistance-associated mutations in the HIV-1 pol gene of B subtype and BF intersubtype recombinant samples. J Acquir Immune Defic Syndr 2004; 35:207-209.
11. Kumar S, Tamura K, Nei M. MEGA 3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform 2004; 5:150-163.
12. Stanford University. HIV Drug Resistance Database. (Updated 2 May 2008. Accessed 1 November 2008.) Available from http://www.hivdb.stanford.edu.
13. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: spring 2008. Top HIV Med 2008; 16:62-68.
14. Lole KS, Bollinger RC, Paranjape RS, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999; 73:152-160.
15. Dilernia DA, Lourtau L, Gomez AM, et al. Drug-resistance surveillance among newly HIV-1 diagnosed individuals in Buenos Aires, Argentina. AIDS 2007; 21:1355-1360. (Pubitemid 46883491)
16. Marcelin AG, Delaugerre C, Wirden M, et al. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 2004; 72:162-165.
17. Wirden M, Lambert-Niclot S, Marcelin A-G, et al. Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1 infected patients. AIDS 2009; 23:95-99.
18. Petroni A, Deluchi G, Zanotto P, Benetucci J. B/F intersubtype recombinants of HIV-1 in Argentina: impact on genotypic patterns associated with antiretroviral drug resistance. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 693.
19. Poveda E, Garrido C, de Mendoza C, et al. Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007; 60:1409-1410. (Pubitemid 350168348)
20. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005; 79:12773-12782.
21. Ait Khaled M, Rakik A, Griffin P, et al. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/ amprenavir in the CNA2007 study. Antivir Ther 2003; 8:111-120.
22. Ceccherini-Silberstein F, Svicher V, Sing T, et al. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. J Virol 2007; 81:11507-11519.
23. Koval CE, Dykes C, Wang J, Demeter LM. Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N+L100I by the nucleoside resistance mutation L74V. Virology 2006; 353:184-192.
24. Demeter LM, DeGruttola V, Lustgarten S, et al. Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials 2008; 9:11-25.
25. Kleim JP, Rosner M, Winkler I, et al. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74->Val or Ile and Val-75->Leu or Ile) HIV-1 mutants. Proc Natl Acad Sci U S A 1996; 93:34-38. (Pubitemid 26041480)
26. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with subtype C, compared to subtypes A and D, after administration of single-dose NVP. J Infect Dis 2005; 192:30-36.
27. Peeters M, Nijs S, Vingerhoets J, et al. Determination of phenotypic clinical cut-offs for etravirine: pooled week 24 results of the DUET-1 and DUET-2 trials. Antivir Ther 2008; 13 Suppl 3:A133.
28. Vingerhoets J, Peeters M, Azijn H, et al. An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. Antivir Ther 2008; 13 Suppl 3:A26.